Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon in Refractory Metastatic Pancreatic Cancer
NCT05766748Phase 2Recruiting
- Sponsor
- Cantex Pharmaceuticals, Inc.
- Start
- Jun 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azeliragon, sponsored by Cantex Pharmaceuticals, Inc.. Started Jun 2023; status: recruiting.
02
Drugs
azeliragon
Beyond the preview
Go deeper on NCT05766748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766748.